secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-047119
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine Q3 net loss $52.5M; BMS collaboration provides $110M upfront
---------------------------------------------------------------------------

- Net loss of $52.5M in Q3 2024 vs. $50.7M in Q3 2023; R&D expenses $40.3M, G&A $14.1M.
- Pro-forma cash $244.6M, sufficient to fund operations into 1H 2026.
- Entered strategic collaboration with Bristol Myers Squibb for ex vivo T-cell therapies; $110M upfront (including $55M equity investment), potential milestones >$3.5B.
- Wilson's Disease program initiated IND-enabling activities; IND/CTA filing expected 1H 2026.
- Phase 1/2 trial of PM359 for p47 phox CGD ongoing; initial clinical data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/0001628280-24-047119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024047119/prme-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer